Menarini inaugurates its China headquarters in Wuhan Biolake

4 November 2013

Family-owned Menarini Group, Italy’s largest biopharma company, has officially launched its China headquarters at the Wuhan National Bioindustry Base (Wuhan Biolake) in Hubei Province.

Menarini says the inauguration of the China headquarters was a key milestone for the company, signifying Menarini’s enhanced presence in the world’s most dynamic market.

“Menarini is rapidly accelerating its growth in the Asia-Pacific region and our growth strategy and China is pivotal to the overall plan. The establishment of Menarini China headquarters as the first wholly-owned foreign pharmaceutical holding company in Wuhan Biolake is therefore a key and vital milestone in the history of Menarini. It is a major leap for us to demonstrate our long-term commitment to help improve the health of Chinese patients and to invest in the world’s fastest growing healthcare market,” said Pietro Giovanni Corsa, general manager of the Menarini Group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK